 Ovarian Cancer: The importance of testing for genomic instability in addition to BRCA1/2 mutations in aOC

Dr. Vail is the director of the clinical molecular pathology laboratory at Cedars-Sinai Medical Center. The laboratory has a full suite of molecular diagnostic assays, encompassing viral, genetic and oncology testing. Dr. Vail’s academic focus is on the effective utilization of genomic biomarkers, especially those provided by NGS, in the clinical setting and provider outreach and education.

In this session, Dr. Eric Vail discusses the importance of genomic instability testing in advanced ovarian cancer patients. The session covers the clinical guidelines and recommendations for BRCA1/2 mutation testing and HRD status assessment through comprehensive genomic instability testing in ovarian cancer patients and its role in informing the use of PARPi therapy.

DXRX Lab Talk: FGFR3 testing in bladder cancer

Furthermore, Dr. Hubank discussed major diagnostic pitfalls that labs should consider when testing for FGFR3 in bladder cancer, including considerations on test selection, sample quality, and interpretation of results. The event also included a Q&A session at the end.

Access this Lab Talk to deep dive into these topics and learn more about FGFR3 diagnostic.

Download the Lab Talk slides

Dr. Michael Hubank has worked in Genomics for over 20 years. Following a PhD at UCL, he worked at the University of Sussex and Yale University before returning to the UCL Institute of Child Health in 2000 to found and run 

. In 2016 he moved into clinical diagnostics at the Royal Marsden Hospital, London, to lead a translational laboratory focused on the development and clinical application of genomic assays for cancer diagnostics. Since 2018 he has been Scientific Director at the NHS England North Thames Genomic Laboratory Hub.

He is a joint investigator on several research projects using multiomic profiling for optimising personalised diagnostics and treatments for childhood cancer patients. He has a strong focus on developing and applying genomic assays, and a particular interest in moving circulating biomarkers into standard of care testing.

In our latest Lab Talk, Dr. Michael Hubank delved into FGFR genomic alterations and their role in cancer, specifically focusing on the clinical utility of FGFR3 alterations in bladder cancer patients. FGFR3 alterations which includes genomic alterations and fusions are especially common in bladder cancer, making FGFR3 a key biomarker for targeted treatment. The session covered the importance of FGFR3 diagnostic journey for bladder cancer patients. 

This Lab Talk took place on 16th September 2024.

NRG1 fusions testing

Speaker name: Kurt A. Schalper, M.D./Ph.D. 

Associate Professor of Pathology and Medicine (Medical Oncology), Yale School of Medicine. Director Translational Immuno-oncology Laboratory, Yale Cancer Center

Dr. Schalper trained as cell/molecular biologist and surgical pathologist. His professional experience includes clinical molecular diagnostics and development of cancer biomarkers. His laboratory focuses on understanding the interaction between molecular oncogenic pathways and immune evasion, and deciphering the structural/functional determinants of the tumor microenvironment in solid tumors. Dr. Schalper is also the director of the Translational Immuno-oncology Laboratory at the Yale Cancer Center where he leads the standardized analysis of biomarkers in clinical trials using advanced cell/tissue analysis platforms.

Our latest Lab Talk with Dr. Kurt Schalper explored pathogenic gene fusions as oncogenic drivers and actionable biomarkers in precision oncology, focusing on NRG1 fusions.

This session will explore the FGFR genomic alterations and their role in cancer, with a focus on the clinical utility of FGFR3 in bladder cancer. Furthermore, Dr. Michael Hubank will explore the bladder cancer patient diagnostic journey, and the technical challenges and considerations in FGFR3 and bladder cancer testing, including considerations on biopsy, test selection, sample quality, and interpretation of results. This event will include a Q&A session at the end, where you can ask Dr. Hubank your questions on this topic.

This Lab Talk took place on 26th September 2024.

Our latest Lab Talk discusses the clinical significance of FGFR3 testing in bladder cancer patients and highlights the technical challenges and considerations in bladder cancer testing.

on the HER2 testing landscape and the need for 

 to optimize performance in the diagnostic process to 

ensure eligible patients receive targeted therapies. 

This Lab Talk took place on 5th June 2024.

DXRX Lab Talk: A new perspective on HER2 testing. Evolving the lab practices to match clinical advances

This session analyzes the clinical utility of HER2 testing, technical considerations (both pre-analytical and analytical), scoring reproducibility and includes a Q&A session with Prof. Dr Abeer Shaaban MBBCh, MSc, PhD, FRC Path​.

FAQs

 Prof. Dr Abeer Shaaban MBBCh, MSc, PhD, FRCPath​

Prof. Dr Shaaban is a Consultant Pathologist at Queen Elizabeth Hospital Birmingham and Professor of Cancer and Genomic Sciences, University of Birmingham, UK.

As the CRUK Birmingham Centre Pathologist, she supported translational and digital pathology & multiplex immunofluorescence studies

She has led a number of research studies and contributed to breast cancer trials as co-investigator, member of a Trial Management Group and as a central pathology reviewer. Her research interest includes profiling tumour microenvironment, tissue microarrays, predictors of response/resistance to therapies and ethnic differences in cancer.

She was member of the NCRI Breast CSG for two terms and acted as chair of the NCRI Breast CSG Translational Subgroup for 5 years. The subgroup produced several landmark publications including guidance on improving the turnaround of HER2 testing, manufacture and reporting of tissue microarrays and handling of neoadjuvant chemotherapy specimens.

Prof. Dr Shaaban published over 150 peer reviewed papers and contributed a number of book chapters including in the WHO Blue Book for Breast tumours 2019 and the International Collaboration on Cancer Reporting (ICCR)DCIS dataset 2021. She co-edited a textbook of molecular pathology entitled “Molecular pathology for the practising surgical pathologist and cytopathologists”. She lectured on a number of UK and international courses/conferences including San Antonio Breast Cancer Symposium, BDIAP, ESSO, EBBC, Pathological Society of Great Britain and Ireland meetings and other. Prof Shaaban organises an annual multidisciplinary breast pathology update course 

http://birminghambreastpathology.org/bbpuc-2021

Prof. Dr Shaaban led the NCRI Cellular and Molecular Pathology initiative (CM-PATH) Workstream 2 (Clinical Trials). She served as member of the International Committee of the Royal College of Pathologists, member of the Scientific Advisory Board of Breast Cancer Now and is Breast Screening Advisor for Public Health England.

This  event  is  sponsored  by  AstraZeneca.  This  content  is  intended  for  healthcare  professionals  only. Z4-62777. Any use and distribution of the information contained in this document must be assessed and approved in accordance with regional/local approval processes to ensure compliance with applicable local laws, regulations, codes and AZ policies.

This content is organized and funded by AstraZeneca. This content is intended for healthcare professionals only. Z4-62777. DOP: June 2024. 

KIT D816V in Patienten Systemischer Mastozytose

Die Systemische Mastozytose ist eine seltene klonale Mastzellneoplasie, die sich durch unkontrollierte Proliferation und Akkumulation von neoplastischen Mastzellen in verschiedenen Organen auszeichnet. Eine SM kann zu einem Spektrum an schweren und beeinträchtigenden Symptomen führen.

Das Seminar bespricht den langen Weg eines SM-Patienten von Verdacht bis zur Diagnose, den klinischen Nutzen der KIT D816V Mutationsanalyse, sowie Faktoren, die zu Fehldiagnosen führen können und erörtert die aktuellen gängigen Richtlinien. Diese Veranstaltung schloss eine Fragerunde ein, in der Prof. Kvasnicka mehrere Fragen zu diesem Thema beantwortete.

Erfahren Sie in diesem Labortalk mehr über KIT D816V bei Systemischer Mastozytose und tauchen Sie tiefer in dieses Thema ein.

Die FAQs zu den KIT D816V-Tests sind jetzt zum Download verfügbar

Prof. Dr. med.Hans Michael Kvasnicka, Direktor Institut für Pathologie und Molekularpathologie

Prof. Dr. Hans Michael Kvasnika ist Direktor des Institut für Pathologie und Molekulare Pathologie Helios Universitätsklinikum Wuppertal und Lehrstuhlinhaber für Pathologie der Universität Witten/Herdecke. Zuvor war Prof. Dr Kvasnicka Chefarzt und stellvertretender Direktor des Senckenberg-Instituts für Pathologie an der Universität Frankfurt. Dort leitete er die Abteilung für Hämatopathologie und Tumorpathologie. Er ist Berater bei einer Reihe von internationalen und klinisch-pathologischen Studien im Auftrag der Weltgesundheitsorganisation (WHO) und ist ausscheidener Vorsitzender des Europäischen Knochenmark Ausschusses (EBMWG). Er hat eine beeindruckende Liste an Veröffentlichungen in Fachzeitschriften und war Mitautor der WHO-Klassifikation von Tumoren der hämatopoetischen und lymphoiden Gewebe.

~90-95% der Patienten mit Systemischer Mastozytose sind KIT D816V-positiv. Testen Sie bereits auf diese schwerwiegende Mutation?

Unser aktuelles Lab Talk, unter der Leitung von Prof. Dr. med. Hans Michael Kvasnicka, Direktor des Instituts für Pathologie und Molekularpathologie, Helios Universitätsklinikum Wuppertal, befasst sich mit der klinischen Bedeutung der KIT D816V Mutation bei Patienten mit Systemischer Mastozytose (SM), einschließlich fortgeschrittener SM (AdvSM) und Indolenter SM (ISM).

Insights

Ovarian Cancer: The importance of testing for genomic instability in addition to BRCA1/2 mutations in aOC

FGFR3 testing in bladder cancer: Recording now available

DXRX Lab Talk: NRG1 fusions testing

FGFR3 testing in bladder cancer

A new perspective on HER2 testing – Evolving the lab practices to match clinical advances

KIT D816V in Patienten mit Systemischer Mastozytose: Die Aufnahme ist jetzt verfügbar!

Ovarian Cancer: The importance of testing for genomic instability in addition to BRCA1/2 mutations in aOC

FGFR3 testing in bladder cancer: Recording now available

DXRX Lab Talk: NRG1 fusions testing

FGFR3 testing in bladder cancer

A new perspective on HER2 testing – Evolving the lab practices to match clinical advances​

KIT D816V in Patienten mit Systemischer Mastozytose: Die Aufnahme ist jetzt verfügbar!

A new perspective on HER2 testing – Evolving the lab practices to match clinical advances